Dalire - indication - references

1. Hurst JR et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. NEJM. 363:12. Sept 16, 2010.
2.Burgel PR, Neseme-Meyer P, Chanez P et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest.
3. DALIRESP (roflumilast) Prescribing Information. Forest Pharmaceuticals, Inc. St. Louis, MO.
4. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated
2010. http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf. Accessed June 12, 2012.